Medical Oncology, Sichuan Cancer Hospital and Institute, Second People's Hospital of Sichuan Province, Chengdu, South China.
Int J Hyperthermia. 2011;27(6):549-54. doi: 10.3109/02656736.2011.593019.
The aim of this retrospective study was to evaluate the technical efficacy and survival following CT-guided radiofrequency ablation (RFA) of liver metastases (LM) from nasopharyngeal carcinoma (NPC) and to determine prognostic factors.
Between 2000 and 2008, 376 patients with LM from NPC were identified. Of these 17 patients with 31 LM from NPC underwent CT-guided percutaneous RFA. We assessed the technical effectiveness, complications and prognostic value of LM characteristics including timing (synchronous versus metachronous), number, size, presence of extra hepatic metastases and treatment regimen. Survival rates were calculated using the Kaplan-Meier method.
Technical success was achieved in 30/31 metastases (96.7%). The median overall survival was 16.5 months from the time of diagnosis of LM for all the 376 NPC patients with LM, and 48.1 months for the 17 NPC patients with LM who received RFA treatment. Of the 376 patients, 111 had 1-3 LM who did not receive RFA treatment, with a median survival of 25.9 months compared to 48.1 months for the 14 patients with 1-3 LM who received RFA.
CT-guided RFA of LM from NPC can be performed with a high degree of technical effectiveness and offers the promise of improved survival in selected patients.
本回顾性研究旨在评估 CT 引导下射频消融(RFA)治疗鼻咽癌(NPC)肝转移瘤(LM)的技术疗效和生存率,并确定预后因素。
2000 年至 2008 年间,共发现 376 例 NPC 合并 LM 的患者。其中 17 例患者共 31 个 LM 接受了 CT 引导下经皮 RFA 治疗。我们评估了包括肿瘤时间(同步与异时)、数量、大小、是否存在肝外转移以及治疗方案等 LM 特征的技术有效性、并发症和预后价值。采用 Kaplan-Meier 法计算生存率。
30/31 个(96.7%)转移灶达到了技术成功。376 例 NPC 合并 LM 患者中,从 LM 诊断开始的中位总生存期为 16.5 个月,17 例接受 RFA 治疗的 NPC 合并 LM 患者的中位总生存期为 48.1 个月。376 例患者中,111 例存在 1-3 个 LM 且未接受 RFA 治疗,其中位生存期为 25.9 个月,而 14 例存在 1-3 个 LM 且接受 RFA 治疗的患者中位生存期为 48.1 个月。
CT 引导下 RFA 治疗 NPC 合并 LM 可获得较高的技术成功率,为部分患者带来了生存获益。